Dew, I agree. It appears that some folks including your Bloomberg article underestimate the importance of Copaxone to Teva by referring to its importance by revenue (+/- 20%) rather than as you've clearly pointed out it's importance to net income of 42% last quarter.
It's ironic that as a widely known generic company with hundreds of products Teva's single most important product is a branded drug.
For MNTA's sake lets hope 40mg approval and launch takes place in 1Q17 as Sandoz should be able to make significant inroads to market share. Yes, jbog, this is only really significant if they are the sole generic for a meaningful period of time.
Market Data 
Markets 
AI
